The prognostic value of serum creatinine on admission in fibrinolytic-eligible patients with acute myocardial infarction

Journal of Thrombosis and Thrombolysis

Volumn 16, Issue 3, 2003, Pages 167-174

  Hobbach, Hans Peter ^a,c   Gibson, C Michael ^b   Giugliano, Robert P ^b   Hundertmark, Julia ^a   Schaeffer, Christel ^a   Tscherleniak, Wassillij ^a   Schuster, Peter ^a  

^a St Marien Krankenhaus Siegen gem GmbH   (Germany)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NONE   (Germany)

Author keywords

Acute myocardial infarction; Percutaneous coronary intervention; Risk factor; Serum creatinine

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CREATININE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOTROPIC AGENT; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOGRAPHY; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; KIDNEY DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE REGRESSION; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; ST SEGMENT ELEVATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

AGED; CREATININE; DIAGNOSTIC TESTS, ROUTINE; FEMALE; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 4344659349     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:THRO.0000024055.13207.50     Document Type: Article

References (38)

1. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on longterm dialysis. N Engl J Med 1998;339:799-805.
2. Al Suwaidi J, Reddan DN, Williams K, et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 2002;106:974-980.
3. Luft FC. Renal disease as a risk factor for cardiovascular disease. Basic Res Cardiol 2000;95:172-176.
4. Asinger RW, Henry TD, Herzog CA, et al. Clinical outcomes of PTCA in chronic renal failure: a case-control study for comorbid features and evaluation of dialysis dependence. J Invasive Cardiol 2001;13:21-28.
5. Vaitkus PT. Current status of prevention, diagnosis, and management of coronary artery disease in patients with kidney failure. Am Heart J 2000 139:1000-1008.
6. Rubenstein MH, Harrell LC, Sheynberg BV, et al. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation 2000;102:2966-2972.
7. Best PJ, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002;39:1113-1119.
8. Januzzi JL, Cannon CP, DiBattiste PM, et al. Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). Am J Cardiol 2002 90:1246-1249.
9. Rao V, Weisel RD, Buth KJ, et al. Coronary artery bypass grafting in patients with non-dialysis-dependent renal insufficiency. Circulation 1997;96:II-38-43; discussion 11-44-45.
10. Liu JY, Birkmeyer NJ, Sanders JH, et al. Risks of morbidity and mortality in dialysis patients undergoing coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group. Circulation 2000;102:2973-2977.
11. Anderson RJ, O'Brien M, MaWhinney S, et al. Renal failure predisposes patients to adverse outcome after coronary artery bypass surgery. VA cooperative study #5. Kidney Int 1999;55:1057-1062.
12. Hirose H, Amano A, Takahashi A, Nagano N. Coronary artery bypass grafting for patients with non-dialysis-dependent renal dysfunction (serum creatinine>or = 2.0 mg/dl). Eur J Cardiothorac Surg 2001;20:565-572.
13. Nakayama Y, Sakata R, Ura M, Itoh T. Long-term results of coronary artery bypass grafting in patients with renal insufficiency. Ann Thorac Surg 2003;75:496-500.
14. Luke RG. Chronic renal failure: a vasculopathic state. Engl JMed 1998 339:841-843.
15. Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 2002 137:563-570.
16. Beatti JN, Soman SS, Sandberg KR, et al. Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Am J Kidney Dis 2001;37:1191-1200.
17. McCullough PA, Sandberg KR, Borzak S, et al. Benefits of aspirin and beta-blockade in patients with chronic kidney disease. Am Heart J 2002 144:226-232.
18. Hillege HL, van Gilst WH, van Veldhuisen DJ, et al. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 2003;24:412-420.
19. Shlipak MG, Heidenreich PA, Noguchi H, et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002;137:555-562.
20. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003;42:201-208.
21. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13-20.
22. PCAT Collaborators. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. Am Heart J 2003;145:47-57.
23. Keeley EC, McCullough PA. Coronary revascularization in patients with end-stage renal disease: risks, benefits, and optimal strategies. Rev Cardiovasc Med 2003;4:125-130.
24. Keeley EC, Kadakia R, Soman S, McCullough PA. Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes. Am J Cardiol 2003;92:509-514.
25. Neuhaus KL, Molhoek GP, Zeymer U, et al. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4. Am Coll Cardiol 1999;34:966-973.
26. Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs. accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000;21:2005-2013.
27. Topol EJ, GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905-1914.
28. Brener SJ, Zeymer U, Adgey AA, et al. Eptifibatide and lowdose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. J Am Coll Cardiol 2002;39:377-386.
29. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen(ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001 358:605-613.
30. Charbonnier B, Pluta W, De Ferrari G, et al. Evaluation of two weight-adjusted single bolus doses of amediplase to patients with acute myocardial infarction: The 3K2 trial. Circulation 2001;104:II-538.
31. Giugliano RP, Roe MT, Harrington RA, et al, on behalf of the INTEGRITI Investigators. Combination reperfusion therapy with eptifibatide and reduced dose tenecteplase for ST-elevation myocardial infarction: Results of Integrilin® and tenecteplase in acute myocardial infarction (INTEGRITI) phase II angiographic trial. J Am Coll Cardiol 2003 ;41:1251-1260ii.
32. Hobbach HP, Giugliano RP, Pfeiffer P, et al. Efficacy and safety of an adjunctive treatment with clopidogrel in patients pretreated with combination thrombolytic therapy. Z Kardiol 2003;92:I/328.
33. Hobbach HP, Gibson CM, Giugliano RP, et al. A new dosing regimen of tirofiban in combination with half-dose tenecteplase in acute myocardial infarction. Eur Heart J 2003;24:546.
34. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000 ;102:2031-2037.
35. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med 1985;312:932-936.
36. Gibson CM, Pinto DS, Murphy SA, et al. for the TIMI Study Group. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol 2003;42:1535-1543.
37. Wolfe RA, Port FK, Webb RL, et al. Experts from the united states renal data system, 1998 annual report: V. Patients mortality and survival. Am J Kidney Dis 1998;32:I69-I80.
38. Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003;107:87-92.